The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|November 18, 2014
CTI Clinical Trial and Consulting Services Opens Geel, Belgium Office
CTI announced that is has opened an office in Geel, Belgium.
Advertisement
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that is has opened an office in Geel, Belgium. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Belgium SPRL. This is the company’s sixth new office opened this year, with additional new offices expected to be announced in the next several months.
“We have had CTI employees in Belgium for the past several years working on behalf of our pharmaceutical and biotechnology clients, but it felt like it was time to formalize an office in the country,” according to Patrick Earley, Vice President, International. “Belgium is desirable for clinical trials due to innovative regulatory agencies, as well as excellent academic centers and researchers, leading to rapid study start up timelines and high enrollment at sites.”
CTI has been working for over fifteen years in the drug development industry in North America, Europe, South America, and Pac-Asia, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5